Here are seven articles published by Becker's Hospital Review in the last week, detailing Gilead Science's $12B takeover of Kite Pharma, the approval of Novartis' revolutionary leukemia drug and more.
1. Blood supplier expects shortages in Texas amid Hurricane Harvey
United Blood Services is calling on Texas residents to donate blood in the wake of Hurricane Harvey.
2. Former pharma CEO: Political interference is 'worst solution' to high drug prices
Former Schering-Plough CEO Fred Hassan told CNBC that the "worst solution" to high drug prices is political interference.
3. Gilead to acquire Kite Pharma for nearly $12B: 4 things to know
Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million.
4. Why this drug study could redefine heart disease treatment
Reducing inflammation — independent of lowering cholesterol — can reduce the risk of heart attacks, according to research sponsored by Novartis and presented Sunday at the European Society of Cardiology in Barcelona.
5. Abbott issues software update to prevent pacemaker hacks: 4 things to know
Abbott Laboratories on Tuesday released a software update to boost cybersecurity protection for its pacemakers.
6. FDA approves Novartis' 'breakthrough' leukemia drug — with a price tag of $475k
The FDA approved Novartis' revolutionary CAR-T cell leukemia therapy, which uses patients' genetically modified immune cells to fight the disease — at the cost of $475,000 per treatment.
7. Couple sues Amazon, claiming eclipse glasses left them with eye damage
A South Carolina couple filed a proposed class action lawsuit against Amazon Tuesday, claiming faulty solar eclipse glasses they purchased from the online retailer gave them eye damage.
More articles on supply chain:
Novartis, CMS collaborate on outcomes-based pricing for $465k leukemia drug
FDA approves Novartis' 'breakthrough' leukemia drug — with a price tag of $475k
Abbott issues software update to prevent pacemaker hacks: 4 things to know